Catalpol prevents denervated muscular atrophy related to the inhibition of autophagy and reduces BAX/BCL2 ratio via mTOR pathway

Drug Des Devel Ther. 2018 Dec 31:13:243-253. doi: 10.2147/DDDT.S188968. eCollection 2019.

Abstract

Aim: To investigate the effects of catalpol on muscular atrophy induced by sciatic nerve crush injury (SNCI).

Methods: Seventy male Kunming mice were randomized into five groups (n=10): model, sham, catalpol (Cat), rapamycin (Rapa), and catalpol+rapamycin (Rapa+Cat). The ratio of gastrocnemius muscle wet weight (right/left, R/L) between the operated leg (right) and the normal leg (left) was calculated, and acetylcholinesterase (AChE) immunohistochemistry assays were performed to observe the change of motor end plate (MEP), along with the sizes of denervated and innervated muscle fibers. The expression levels of LC3II, TUNEL, BAX/BCL-2, LC3II/LC3I and P62, Beclin1, mTOR, and p-mTOR (ser2448) proteins in muscle were examined by fluorescence immunohistochemistry or Western blotting.

Results: Results show that catalpol improved the results of the grid walking tests by reducing the percentage of foot slips, which increased the gastrocnemius muscle wet weight (R/L), enhanced AChE expression at the MEP, and enlarged the section area of the muscle. The expression of LC3II and TUNEL was significantly inhibited by catalpol. The BAX/BCL-2 ratio was significantly increased in muscles of denervated and control groups. Lower LC3II/LC3I and BAX/BCL-2 ratios in denervated muscles were also detected after catalpol treatment.

Conclusion: These results indicated that apoptosis and autophagy play a role in the regulation of denervation-induced muscle atrophy after SNCI, and catalpol alleviates muscle atrophy through the regulation of muscle apoptosis and autophagy via the mTOR signaling pathway.

Keywords: SNCI; autophagy; catalpol; denervated muscle atrophy; muscle apoptosis; sciatic nerve crush injury.

MeSH terms

  • Animals
  • Autophagy / drug effects*
  • Dose-Response Relationship, Drug
  • Iridoid Glucosides / pharmacology*
  • Male
  • Mice
  • Mice, Inbred Strains
  • Muscular Atrophy / drug therapy*
  • Muscular Atrophy / pathology
  • Proto-Oncogene Proteins c-bcl-2 / metabolism*
  • Signal Transduction / drug effects
  • Structure-Activity Relationship
  • TOR Serine-Threonine Kinases / metabolism*
  • bcl-2-Associated X Protein / metabolism*

Substances

  • Bax protein, mouse
  • Iridoid Glucosides
  • Proto-Oncogene Proteins c-bcl-2
  • bcl-2-Associated X Protein
  • Bcl2 protein, mouse
  • catalpol
  • mTOR protein, mouse
  • TOR Serine-Threonine Kinases